Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 05:15:55 2024-07-08 am EDT 5-day change 1st Jan Change
92.77 EUR +2.01% Intraday chart for Sanofi +1.02% +3.38%
Sales 2024 * 46.33B 50.23B Sales 2025 * 49.75B 53.94B Capitalization 114B 123B
Net income 2024 * 7.07B 7.66B Net income 2025 * 8.57B 9.3B EV / Sales 2024 * 2.6 x
Net Debt 2024 * 6.96B 7.55B Net Debt 2025 * 2.53B 2.74B EV / Sales 2025 * 2.34 x
P/E ratio 2024 *
16.4 x
P/E ratio 2025 *
13.3 x
Employees 86,088
Yield 2024 *
4.25%
Yield 2025 *
4.48%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.96%
1 week+0.95%
Current month+3.09%
1 month+2.71%
3 months+6.57%
6 months-1.50%
Current year+3.30%
More quotes
1 week
89.77
Extreme 89.77
92.78
1 month
85.94
Extreme 85.94
92.78
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
104.32
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-07-08 92.77 +2.01% 186 073
24-07-05 90.94 -0.07% 1,024,381
24-07-04 91 +0.85% 851,243
24-07-03 90.23 -0.23% 1,538,011
24-07-02 90.44 -1.54% 1,598,990

Real-time Euronext Paris, July 08, 2024 at 05:00 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
90.94 EUR
Average target price
108.1 EUR
Spread / Average Target
+18.86%
Consensus